At Celldex, we are committed to developing safe and effective therapies for patients with devastating diseases for which available treatments are inadequate.
We understand the importance of bringing these therapies to the broadest group of patients as quickly as possible. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease.
Clinical studies collect the information necessary to understand the safety and efficacy of the potential therapy allowing for regulatory review and potential approval.
Visit here to learn more about our Compassionate Use or Expanded Access Program.
|Barzolvolimab||Phase 2 [Completed Enrollment]||External link opents in a new window NCT05368285||Chronic Spontaneous Urticaria|
|Barzolvolimab||Phase 2||External link opents in a new window NCT05405660||Chronic Inducible Urticaria (Cold Contact Urticaria, Symptomatic Dermographism)|
|Barzolvolimab||Phase 2||External link opents in a new window NCT05774184||Eosinophilic Esophagitis|